Kort kommentar fra SEB til Q1 regnskabet fra Fluoguide:
FluoGuide reported Q1 EBIT of DKK 4.2m (vs. SEB at DKK 10.3m) and EPS of DKK 0.32 (vs. SEB at DKK 0.77). The key milestones for 2021 remains 1) results from the first phase clinical study (safety and selection of optimal dose) by Q321, 2) efficacy results from the second phase by Q421 as well as 3) initiation of a new prevalent indication for FG001. Nothing in the report that changes our view on the case.